Results 31 to 40 of about 171,342 (310)
BMC Complementary Medicine and Therapies, 2021 Background Melanoma and breast cancers are two common cancers worldwide. Due to the side effects of chemotherapy drugs and the occurring resistance against them, the development of green drugs has been received more attention.
Hiva Alipanah +4 more
doaj +1 more source
Neoadjuvant therapy for breast cancer [PDF]
, 2019 Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area.
Carrozzi G. +10 more
core +1 more source
Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan
Cureus, 2022 Background The term triple-negative breast cancer (TNBC) refers to a particular class of aggressive, poorly differentiated neoplasms that show the absence of estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) antibodies.
Seema Ali +4 more
semanticscholar +1 more source
Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]
, 2016 Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana +5 more
core +3 more sources
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
Virchows Archiv, 2021 Triple-negative breast carcinomas constitute a wide spectrum of lesions, mostly being highly aggressive. Nevertheless, some special histologic subtypes can have low malignant potential.
L. Cima +6 more
semanticscholar +1 more source
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. [PDF]
, 2017 CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play an important role in tumor progression. Tested to date CXCR1/2 antagonists and chemokine-targeted antibodies were reported to affect malignant cells in vitro and in animal models.
Alexeev, Vitali +10 more
core +2 more sources
Results of clinical developments of early triple negative breast cancer drug treatment: ASCO - 2022
City Healthcare, 2022 Introduction. This article continues the series of reviews of innovative clinical developments related to drug therapy for leading cancers following the ASCO-2022 Annual Congress.
D. Andreev, A. Zavyalov
semanticscholar +1 more source
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
Post-translational modifications in mammary gland development and mammary tumor progression [PDF]
, 2015 Breast cancer is one of the most common cancers in women. Estrogen receptor α (ERα) signaling and p53 signaling have important roles in breast cancer progression.
Zhuang, Ting
core +1 more source